Letter on «(1,3)-beta-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial»

Crit Care. 2021 Feb 9;25(1):55. doi: 10.1186/s13054-020-03450-z.

NO ABSTRACT

PMID:33563306 | PMC:PMC7874441 | DOI:10.1186/s13054-020-03450-z